B
Barry R. Davis
Researcher at University of Texas at Austin
Publications - 351
Citations - 50989
Barry R. Davis is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Chlorthalidone & Amlodipine. The author has an hindex of 78, co-authored 342 publications receiving 47899 citations. Previous affiliations of Barry R. Davis include Tulane University & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Sex-specific effects of AGT-6 and ACE I/D on pulse pressure after 6 months on antihypertensive treatment: the GenHAT study.
Amy I. Lynch,Donna K. Arnett,Barry R. Davis,Eric Boerwinkle,Charles E. Ford,John H. Eckfeldt,Cathie Leiendecker-Foster +6 more
TL;DR: This study addresses whether two renin‐angiotensin‐aldosterone system (RAAS) variants are associated with PP in a sex‐specific manner (genotype‐by‐sex interaction) and investigates whether gender may be an effect modifier between PP and cardiovascular disease.
Journal ArticleDOI
Operational aspects of terminating randomization in the multicenter trial of cryotherapy for retinopathy of prematurity
Earl A. Palmer,Robert J. Hardy,Barry R. Davis,Judith A Stein,Richard L. Mowery,Betty Tung,Dale L. Phelps,David B. Schaffer,John T. Flynn,Cynthia L. Phillips +9 more
TL;DR: The Multi-Center Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) as discussed by the authors is a randomized clinical trial sponsored by the National Eye Institute (NEI) designed to test whether cryotherapy applied to eyes of premature infants with a specified extent of stage 3+ ROP significantly decreases the incidence of an unfavorable outcome.
Journal ArticleDOI
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
TL;DR: Evolving ECG LVH and BP change account for 4% to 13% of the mechanism by which antihypertensive medications prevent HF.
Journal ArticleDOI
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
Sanket S. Dhruva,Chenxi Huang,Erica S. Spatz,Erica S. Spatz,Andreas Coppi,Frederick Warner,Shu-Xia Li,Haiqun Lin,Xiao Xu,Curt D. Furberg,Barry R. Davis,Sara L. Pressel,Ronald R. Coifman,Harlan M. Krumholz +13 more
TL;DR: Heterogeneity in response to antihypertensive therapies is demonstrated and chlorthalidone is associated with more favorable initial response than the other medications and provided superior discrimination for predicting downstream adverse cardiovascular events.
Journal ArticleDOI
Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Thomas A. Dewland,Elsayed Z. Soliman,Jose-Miguel Yamal,Barry R. Davis,Alvaro Alonso,Christine M. Albert,Lara M. Simpson,L. Julian Haywood,Gregory M. Marcus +8 more
TL;DR: Treatment with lisinopril is not associated with a meaningful reduction in incident AF or AFL among older adults with a history of hypertension, as indicated by a secondary analysis of the ALLHAT trial.